Tiziana Life Sciences files IND application with FDA for ALS Phase 2 trial

Tiziana Life Sciences (TLSA) announced the submission of its Investigational New Drug, IND, application to the U.S. Food and Drug Administration, FDA, for a phase 2 clinical trial in ALS. This pivotal step marks a significant advancement in the company’s commitment to advance a new treatment approach for Amyotrophic Lateral Sclerosis, ALS, which is supported by the ALS Association. This IND filing follows the prestigious award of a grant as part of the Hoffman ALS Clinical Trial Awards Program from the ALS Association. Tiziana’s intranasal foralumab development programs are now focused on 3 neurodegenerative diseases. ALS, Multiple Sclerosis, and Alzheimer’s disease. This grant provides a framework for industry-academia collaboration where new discoveries are translated to clinical studies through innovative research and development.